Joincare(600380)2024-08-29 07:39Financial Performance - In the first half of 2024, the company achieved operating revenue of 8.235 billion CNY, a decrease of 5.56% year-on-year [2] - The net profit attributable to shareholders was 776 million CNY, down 4.78% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 762 million CNY, a decline of 2.54% year-on-year [2] Business Segment Analysis - Chemical preparations generated operating revenue of 4.074 billion CNY, a decrease of 9.01% year-on-year [2] - Sales in the hormone field reached 1.549 billion CNY, down 12.51% [2] - Sales in the digestive tract field were 1.301 billion CNY, with a year-on-year decline [2] - Sales in the respiratory field were 602 million CNY, down 25.50% [2] - Sales in the mental health field increased by 6.68% to 297 million CNY [2] - Sales in the anti-infection field were 210 million CNY, down 29.96% [2] - Chemical raw materials and intermediates achieved operating revenue of 2.644 billion CNY, a decrease of 1.45% [2] - Traditional Chinese medicine preparations saw revenue of 1.080 billion CNY, down 21.00% [2] - Diagnostic reagents and equipment generated revenue of 394 million CNY, an increase of 32.33% [2] - Health food revenue reached 180 million CNY, a significant increase of 106.37% [2] R&D and Innovation - The company is increasing R&D investment and enhancing its independent R&D capabilities while introducing multiple innovative drug projects [3] - The health food segment is expected to continue its rapid growth, driven by sustained investments and brand development [3] - The company is focusing on innovative drug projects in respiratory, digestive, mental health, and reproductive assistance fields [5] Market Strategy - The company is optimizing market investments and reducing sales expense ratios in response to industry trends [4] - Future sales strategies will focus on enhancing product market share and expanding new product lines [4] - The company is actively preparing for the market launch of new products, including TG-1000, an innovative anti-influenza drug [4][5] Regulatory and Market Environment - The sales of certain products are subject to uncertainties due to changes in domestic pharmaceutical policies and market conditions [4][5] - The company is adapting to the evolving market landscape and regulatory environment to ensure sustainable growth [5]